drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Humanized IgG1 monoclonal antibody targeting HER2; binds domain II to block HER2 heterodimerization with HER3/EGFR, suppress ligand-dependent signaling, and enhance ADCC.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody against HER2 that binds extracellular domain II to prevent HER2 heterodimerization (especially with HER3/EGFR), blocking ligand‑dependent HER signaling (PI3K/AKT, MAPK), inhibiting tumor growth and promoting apoptosis; Fc region mediates antibody‑dependent cellular cytotoxicity (ADCC).
drug_name
Pertuzumab
nct_id_drug_ref
NCT05786716